Marksans Pharma Q4FY17 standalone net profit declines 88.8% yoy

May 29, 2017 01:05 IST India Infoline Research Team

Marksans Pharma Ltd Q4FY17

Standalone Results Q4FY17: (Rs. in crore)

Q4FY17 YoY (%)
Revenue 54 [21.7]
EDITDA 4 [42.9]
EBITDA Margin (%) 7.4 [273]
Net Profit (adjusted) 0.57 [88.8]
***EBITDA margin change is bps
View

Accumulate

Reco. Price

44.4

Last updated on

29-May-2017


Marksans Pharma standalone revenue for the quarter came in at Rs. 54 crore, registering 21.7% yoy decline.

EBITDA for the quarter fell by 42.9% yoy to Rs. 4 crore with a corresponding margin contraction of 273 bps. EBITDA margin for the quarter stood at 7.4%. This margin contraction was driven by 19% yoy increase in employee benefit expenses.

The PAT for the quarter came in at Rs. 0.57 crore, yoy decline of 88.8%. This was backd by 31% yoy increase in finance cost.

Looking at the full year numbers, we see that revenue slided by 40% to reach Rs.215.84 crore while EBITDA fell by 77% to 24.27 crore. Company reported net profit of Rs.12.22 crore, down 83% yoy.

The board has recommended dividend of Rs. 0.05 per share for the face value of Rs. 1 each.



Technical View:

Marksans Pharma Ltd is currently trading at Rs. 42.6, down by 3.75 points or 8.09% from its previous closing of Rs. 46.35 on the BSE.
The scrip opened at Rs. 46.7 and has touched a high and low of Rs. 46.8 and Rs. 42.45 respectively. So far 5691273(NSE+BSE) shares were traded on the counter. The stock is currently trading above its 50 DMA.

Related Story

Open Free Demat Account (Rs699)